Abstract: A process for the production of aminoglycoside antibiotics using fused protoplasts derived from streptomyces. The cells are precultured in a medium containing sucrose, calcium and magnesium salts. Protoplasts are formed and then fused. The fused protoplasts are regenerate and antibiotic producing ability is screened for. The regenerate cells produced an antibiotic complex of modified composition or demonstrated increased or reduced antibiotic productivity compared to the fusion partners.

Abstract: Improved expression vectors for amplifying expression of DNA sequence encoding a desired polypeptide beyond that expected by the vector copy number. The vector contains a DNA sequence within the replicon of the vector encoding RNA I and the primer RNA for initiation of DNA replication and their regulatory regions, said DNA sequence having an AT to GC mutuation at position 3029 in the two strands of pBR322; a promoter of RNA I or primer RNA and a restriction site for insertion of a DNA sequence encoding a desired polypeptide into the vector and operatively linking the DNA sequence to the expression control sequence. The AT to GC mutation causes an increase in the vector copy number and further amplifies the expression of the desired polypeptide operatively linked to the RNA I or primer RNA promoter beyond that expected by the copy number increase.

Abstract: A bacterial insecticide containing an insecticidal substance produced by a practically reversionless asporogenous mutant of Bacillus thuringiensis, especially Bacillus thuringiensis serovar. kurstaki 290-1 and the process for the production in addition to a practically reversionless asporogenous mutant of Bacillus thuringiensis, especially Bacillus thuringiensis serovar. kurstaki 290-1 and the process for the production.

Abstract: The present invention discloses permanent establishment of an immortal line of fetal glial cells. The fetal glial cell line is capable of mitotically proliferating and continually growing in vitro under suitable culture media and environmental conditions. A method of producing immortalized human fetal glial cell line is also disclosed. The method comprises transfecting primary human fetal glial cells with an origin-defective mutant of SV40 virus, passaging the resulting astroglial cells through suitable number of cycles and obtaining the desired cell line. The cell line of the present invention is capable of supporting multiplication of JC virus.

Abstract: An expression vector carrying a gene coding for a phosphate-binding protein has been found to have a strong gene expression. The expression vector can be produced by transforming a bacterium belonging to Enterobacteriaceae with a recombinant vector carrying a DNA fragment containing a gene coding for a phosphate-binding protein to form transformants, selecting the transformants containing the desired recombinant vector from said transformants, and isolating the desired recombinant vector from the selected transformants. The expression vector is useful for producing polypeptides.

Abstract: Periplasmic proteins are recovered from transformed gram negative bacteria by a process comprising freezing and thawing the cells. Advantages are obtained by culturing the cells in phosphate-limiting media and by killing the cells prior to separation of periplasmic proteins.

Abstract: A monoclonal antibody 4A produced by a human-mouse hybridoma cell line is described. In the presence of complement, 4A subsets both cytotoxic and helper T cells creating a diagnostic tool in blood biochemistry.

Abstract: The present invention discloses a new line of endothelial cell of adrenal medullary origin capable of producing blood clotting Factor VIII:C. A method of isolating and culturing said cell line has also been disclosed. Factor VIII:C is useful in treating hemophilia.

Abstract: A method for isolating the fusion product of two cell populations is disclosed. The method involves the introduction of a specific antitoxin into cells of one population while introducing a second specific antitoxin into cells of the second population. After fusing cells of the first population with those of the second population, the fusion product may be selectively isolated on a medium containing an appropriate amount of both first and second toxins. For some applications, it may be appropriate to introduce an antitoxin into only one of the cell populations and isolate the fusion product on a media containing only one toxin.

Abstract: The invention discloses an in vivo method for transforming and regenerating intact plants. According to the method, a plant (P) is infected with an infectious microbial agency comprised of: (1) virulence functions, (2) oncogenic factors capable of inducing a shoot-bearing shooty tumor on plant (P), and (3) a carrier vector containing engineered heterologous transfer DNA capable of being integrated into the nuclear DNA of plant (P) cells. Infected plant (P) is maintained until a shoot-bearing shooty tumor develops at or near the infection site. Those shoots, or progeny thereof, that contain transformed cells having heterologous transfer DNA integrated into their genomes are the selected and utilized to produce whole plants that contain cells having heterologous transfer DNA integrated into their genomes.

Abstract: The present inventiona is directed to a mammalian serum-originated growth factor-containing composition useful in cell cultivation. The composition of the present invention is substantially free of active microorganisms and other harmful substances which would otherwise interfere with cell cultivation. Preferably the composition of the present invention is totally free of contaminant microorganisms, i.e., is sterile.The present invention is also directed to a method of producing the composition of the invention. One step of this method comprises the inactivation of any contaminant microorganisms present in the starting serum. Another step comprises the salting out and desalting of the starting serum to obtain a fraction of the serum which contains the desired cell growth factor. Either step may be conducted first.

Abstract: A method for producing continuous B lymphocyte cell lines and monoclonal antibodies by such lines is provided. DNA isolated from neoplastic cells is introduced into stimulated lymphocytes. Individual cells that have been transformed by the added DNA and that produce antibodies are clonally expanded. Cultures of these continuous cells are employed to produce monoclonal antibodies.